Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.

@article{Razonable2004ValganciclovirFT,
  title={Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.},
  author={Raymund Rabe Razonable and Carlos V. Paya},
  journal={Expert review of anti-infective therapy},
  year={2004},
  volume={2 1},
  pages={27-41}
}
Valganciclovir (Valcyte, Roche), a prodrug of the deoxyguanosine analog ganciclovir (Cytovene, Roche), is indicated for induction and maintenance treatment of cytomegalovirus retinitis in patients with AIDS and for prevention of cytomegalovirus disease in selected high-risk solid organ transplant recipients. After oral administration, valganciclovir is rapidly absorbed and converted to ganciclovir by intestinal and hepatic esterases. Valganciclovir is a highly recognized substrate of the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…